Provided by Tiger Fintech (Singapore) Pte. Ltd.

Travere Therapeutics, Inc.

21.64
+0.49002.32%
Post-market: 21.640.00000.00%18:49 EDT
Volume:3.91M
Turnover:84.89M
Market Cap:1.93B
PE:-10.82
High:22.24
Open:21.36
Low:21.19
Close:21.15
52wk High:25.29
52wk Low:10.64
Shares:89.14M
Float Shares:79.29M
Volume Ratio:1.39
T/O Rate:4.94%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9993
EPS(LYR):-4.0759
ROE:-705.73%
ROA:-19.28%
PB:58.90
PE(LYR):-5.31

Loading ...

Aug 06, 2025

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 06, 2025

Major Issues Report

Form 8-K - Current report
Jun 17, 2025

Employee Stock Ownership

Form S-8 - Securities to be offered to employees in employee benefit plans
May 16, 2025

Major Issues Report

Form 8-K - Current report
May 15, 2025

Major Issues Report

Form 8-K - Current report
May 05, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
May 05, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
May 05, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
May 05, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
May 05, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
May 01, 2025

Major Issues Report

Form 8-K/A - Current report: [Amend]
May 01, 2025

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 01, 2025

Major Issues Report

Form 8-K - Current report
Apr 30, 2025

Major Issues Report

Form 8-K - Current report
Apr 11, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Mar 17, 2025

Major Issues Report

Form 8-K - Current report
Feb 21, 2025

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 20, 2025

Major Issues Report

Form 8-K - Current report
Feb 12, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Feb 12, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities